Please login to the form below

Not currently logged in
Email:
Password:

variants

This page shows the latest variants news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

Gilead’s Veklury receives FDA approval for non-hospitalised high-risk patients to treat COVID-19

variant. Veklury works by targeting the viral RNA polymerase, retaining activity against severe SARS-CoV-2 variants, with in vitro laboratory trials demonstrating Veklury’s effectiveness in retaining activity against the ... So far, there have been no

Latest news

More from news
Approximately 14 fully matching, plus 189 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....